Amgen, Inc. previously specialized in large therapeutic areas like cardiovascular diseases and inflammation, but added a big focus on medicines for rare diseases through its $27.8bn acquisition of Horizon Therapeutics plc last year. Now that the Horizon products and its research and development programs are in Amgen’s hands, the big biotech is going public with its plans for driving growth in rare diseases now and in the future.
Key Takeaways
-
Amgen’s rare disease portfolio generated almost $4bn in 2023 sales, almost entirely from the Horizon assets, and the company expects growth in 2024 and beyond after applying its ex-US, R&D and manufacturing expertise.
-
Increased awareness is key for Tepezza, Krystexxa, Uplizna and Tavneos as well as sales outside of the US and, for Tepezza and Krystexxa, subcutaneous or less frequent I.V. dosing
Executive vice president of global commercial operations Murdo Gordon kicked off a rare disease day that Amgen hosted for analysts and investors on 22 February by reiterating the company’s expectation that the Horizon purchase will be accretive to earnings right away, beginning in 2024. (Also see "Amgen Absorbs Horizon, Pitches Plans For New Rare Disease Growth Engine" - Scrip, 31 October, 2023
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
